IBRX

Immunitybio Inc

• Seeking Alpha·1d ago

  FDA, Duke-Margolis workshop to examine evidence standards for rare diseases

• NASDAQ·4d ago

  ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

• Seeking Alpha·09/08 16:03

  Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

• TipRanks·09/08 11:25

  ImmunityBio (IBRX) Gets a Buy from Piper Sandler

• Seeking Alpha·09/03 13:54

  ImmunityBio: None Of The Moonshots Is Priced In

• Seeking Alpha·09/03 10:36

  Moderna: Massive Asymmetry About What The mRNA Is!

• Seeking Alpha·08/26 21:49

  ImmunityBio: ANKTIVA Is Real, The Valuation Isn't

• Seeking Alpha·08/21 06:10

  BUZZ Investing: Markets Look Through Intra-Period Volatility

• TipRanks·08/10 13:40

  Unusually active option classes on open August 10th

• TipRanks·08/10 13:10

  ImmunityBio appoints Kim as Vice Chairman

• Dow Jones·08/10 13:02

  *ImmunityBio: Kim Will Serve in a Newly Created Office of the Executive Chmn >IBRX

• TipRanks·08/05 10:25

  BTIG’s Mukherjee Reiterates Buy on ImmunityBio as ANKTIVA Growth, Upcoming QUILT-2.005 Milestones Support Unchanged $12 Price Target

• TipRanks·08/04 18:05

  ImmunityBio: ANKTIVA’s Sustained Growth and Regulatory Catalysts Support Reaffirmed Buy Rating and Unchanged $15 Price Target

• NASDAQ·08/04 12:50

  ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

• Dow Jones·08/04 11:31

  *ImmunityBio 2Q Loss/Shr 22c >IBRX